High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites

• DOI: 10.1182/blood.2019001185
• Publication Date: 2019-07-31T22:05:30Z
• Authors: Suraya Elfrink; Charlotte M. de W...; Michiel van den B...; Madeleine Berendsen; Margaretha G. M. ...; Frank Arnold; Luuk Janssen; Alie van der Schaaf; Erik Jansen; Patricia J. T. A....; Astrid Eijkelenboom; Wendy Stevens; Corine J. Hess; J. Han van Krieken; Joost S. P. Vermaat; Arjen H. G. Cleven; Ruben A. L. de Groen; Viviana Neviani; Daphne de Jong; Sjoerd van Deventer; Blanca Scheijen; Annemiek B. van S...
• Keywords: Central Nervous System; Male; 0301 basic medicine; Tetraspanins; DNA Mutational Analysis; lymphoma; Immune Privilege; Central Nervous System Neoplasms; Cohort Studies; 03 medical and health sciences; All institutes and research themes of the Radboud University Medical Center; Radboudumc 2: Cancer development and immune defence RIMLS: Radboud Institute for Molecular Life Sciences; Gene Frequency; Testicular Neoplasms; Antigens, Neoplasm; b-lymphocytes; Testis; Humans; Gene Silencing; mutation analysis; Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences; Radboudumc 9: Rare cancers RIHS: Radboud Institute for Health Sciences; Radboudumc 9: Rare cancers RIMLS: Radboud Institute for Molecular Life Sciences; 3. Good health; diffuse large b-cell lymphoma; Mutation; Female; Tumor Escape; pan-hematopoietic expression protein; Lymphoma, Large B-Cell, Diffuse; mutation

Key Points Loss-of-function mutations in CD37 occur predominantly in diffuse large B-cell lymphoma at immune-privileged sites. CD37-mutated lymphoma B cells show impaired CD37 cell-surface localization, which may have implications for anti-CD37 therapies.